Cole L A, Schwartz P E, Wang Y X
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06510.
Gynecol Oncol. 1988 Sep;31(1):82-90. doi: 10.1016/0090-8258(88)90273-9.
UGF is a mixture of human chorionic gonadotropin free beta-subunit and its fragments, and is detected in pregnancy and trophoblast disease urines. An examination of 67 nonpregnant cancer-free women showed average urine levels of 0.13 ng/ml. Six of the 67 (8.9%) had levels exceeding a selected cutoff value, 0.2 ng/ml. Of 112 woman with active gynecologic cancer, 72 (64%) had urine UGF levels exceeding this cutoff value. When urines were limited to those with creatinine greater than 0.5 mg/ml, or to first morning samples (mean creatinine 1.0 ng/ml), the sensitivity of UGF for all gynecologic cancers was raised to 76%. The sensitivity of UGF for cervical (73%), for endometrial (65%), and for ovarian (83%) cancers exceeded that of plasma CA 125 and lipid-associated sialic acid in plasma (LASA) in the same population. UGF is an exciting new tumor marker which warrants further evaluation.
尿促性腺激素片段(UGF)是游离人绒毛膜促性腺激素β亚基及其片段的混合物,可在妊娠尿液和滋养层疾病尿液中检测到。对67名未怀孕且无癌症的女性进行检测,结果显示尿液平均水平为0.13 ng/ml。67名女性中有6名(8.9%)的水平超过选定的临界值0.2 ng/ml。在112名患有活动性妇科癌症的女性中,72名(64%)的尿液UGF水平超过该临界值。当尿液限制为肌酐大于0.5 mg/ml的尿液或首次晨尿样本(平均肌酐1.0 ng/ml)时,UGF对所有妇科癌症的敏感性提高到76%。在同一人群中,UGF对宫颈癌(73%)、子宫内膜癌(65%)和卵巢癌(83%)的敏感性超过血浆CA 125和血浆脂质相关唾液酸(LASA)。UGF是一种令人兴奋的新型肿瘤标志物,值得进一步评估。